A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors

ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors. Phase 1a will use sequential dose escalation to determine the maximally tolerated dose and biologically effective dose. Phase 1b will randomize participants with CCNE1 amplification between two dose levels to select the recommended Phase 2 dose.

Trial Details

NCT ID
NCT07524140
Phase
PHASE1
Sponsor
Eilean Therapeutics
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • ZE94-0605
Locations (sample)
  • Kogarah, New South Wales, Australia|-33.9681,151.13564
  • Bedford Park, South Australia, Australia|-35.02204,138.56815
  • Tashkent, Uzbekistan|41.26465,69.21627

Key Eligibility Criteria

  • Phase 1a Dose-Escalation Cohorts:
  • Age ≥18 years, with a pathologically confirmed, advanced, unresectable or metastatic solid tumor refractory to, or intolerant of, available therapi…
  • Phase 1b Dose-Expansion Cohorts:
  • Age ≥18 years, with a pathologically confirmed, advanced, unresectable or metastatic solid tumor refractory to, or intolerant of, available therapi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →